Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

Author's Avatar
Mar 11, 2021
Article's Main Image

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today reported financial results for the year ending December 31, 2020 and announced objectives for 2021.